Hacker group claims Chinese bid for stolen Novo data

Earlier this year, Novo Nordisk was hit by a high‑profile data breach in which a large amount of sensitive information was stolen. Now a hacker group claims tha...

ZEISS Innovation Summit returns to Berlin

Gain insights from experts for future-ready quality assurance.

Lantheus challenges Eli Lilly with FDA-approved Alzheimer’s tracer

Eli Lilly has until now had the US market for tau PET imaging in Alzheimer’s disease to itself. The pharmaceutical giant is now facing competition after the FDA...

AstraZeneca scraps late‑stage study – and reports dual successes in lung cancer

AstraZeneca is discontinuing a global Phase III trial that has been evaluating the antibody volrustimig for non‑small cell lung cancer after the chances of succ...

Ensuring Safety and Compliance for IVD Products

In vitro diagnostic medical devices (IVDs) play a crucial role in diagnosis and treatment, as a significant proportion of healthcare decisions are based on labo...

Life Science Nordic launches – bringing Nordic life science news under one roof

Welcome to Life Science Nordic – your source for the news and insights shaping the Nordic life science and medtech industries. We provide independent, in-depth ...

Hansa chair: “Too many boards spend far too much time looking inwards”

Following a change of chief executive and a sharper strategic focus, Hansa Biopharma is entering a decisive phase in the US market. As the company prepares for ...

Gold Rush in Oral Peptides: “Everybody Wants In”

After Ozempic, pharmaceutical companies are racing toward the next big revolution: peptides that can be swallowed as easily as they can be injected. Cyprumed is...

EMA opens review of Europe’s first potential Lyme disease vaccine

The European Medicines Agency (EMA) has validated Valneva’s and Pfizer’s application for approval of the companies’ Lyme disease vaccine, meaning it is now read...

Tuff vecka för Fresenius Kabi – dubbla återkallanden

Fresenius Kabi återkallar ett parti av en av sina biosimilarer i USA sedan produkten visat sig innehålla glaspartiklar. Missen uppdagades bara en vecka efter at...

Ny finanschef till Biolamina

Biotechbolaget Biolamina, verksamt inom cellodling och stamcellsteknik, har rekryterat Sofia Helgesson som finanschef (CFO).

Thermo Fishers mikrobiologiverksamhet byter ägare

Thermo Fisher har nu genomfört försäljningen av sin mikrobiologienhet till ett privat riskkapitalbolag, som kommer att driva verksamheten vidare som ett självständigt bolag.

Phase III win for LSD‑based anxiety drug

An LSD‑based drug candidate for anxiety disorders is reported to show strong results in late‑stage clinical testing.

EU approves Rinvoq for severe patchy hair loss

AbbVie’s well‑known rheumatoid arthritis drug Rinvoq has now been approved in the EU for a completely different indication: severe alopecia areata, or patchy hair loss.

Lilly sues six companies over black market sales of experimental weight loss drug

Eli Lilly is suing six companies in the United States accused of selling illegal versions of the company’s upcoming triple‑acting weight‑loss drug, retatrutide.

Läkemedel mot reumatism får grönt ljus för håravfall

Abbvies välkända reumatismläkemedel Rinvoq har nu EU‑godkänts för en helt annan indikation: svår alopecia areata, eller fläckvis håravfall.

Low-profile Danish biotech recruits Mikael Dolsten

Danish biotech company Quantumcell has quietly assembled a heavyweight group of investors, including Novo Holdings and the Lundbeck Foundation. Following its mu...

Framgång i fas III för LSD-baserad tablett mot ångest

En LSD‑baserad läkemedelskandidat mot ångestsyndrom rapporteras visa starka resultat i sen klinisk fas.

Dansk doldis värvar Mikael Dolsten

Det danska biotechbolaget Quantumcell har i det tysta byggt upp en tung ägarkrets med bland andra Novo Holdings och Lundbeckfonden. Efter miljardavtalet med sve...

Eli Lilly till domstol för att stoppa svarthandel med ”triple-G”

Eli Lilly stämmer sex aktörer i USA som anklagas för att sälja olagliga versioner av bolagets kommande trippelverkande viktminskningsläkemedel retatrutid.

Nyt fra bestyrelser og direktioner i medtechbranchen

WSA får ikke fornyet stor kontrakt med amerikansk managed care-kunde

CF drug flops in phase II — shares collapse

A new experimental treatment for cystic fibrosis failed unexpectedly in phase II — and Sionna Therapeutics’ share price dropped by more than 90 percent.

XVIVO’s heart technology receives CE certificates

XVIVO has been granted CE certification for its preservation and transport system for donor hearts — allowing it to be used clinically in Europe. ”This is a pro...